Foghorn blows its klaxon, gunning for a $100M IPO hot on the heels of its Merck deal

Preclinical biotech Foghorn Therapeutics is aiming for a $100 million IPO, but don’t be surprised it if goes the way of many other biotech listings and shoots far north of that.